BR112022020786A2 - Agente terapêutico de câncer de mama - Google Patents
Agente terapêutico de câncer de mamaInfo
- Publication number
- BR112022020786A2 BR112022020786A2 BR112022020786A BR112022020786A BR112022020786A2 BR 112022020786 A2 BR112022020786 A2 BR 112022020786A2 BR 112022020786 A BR112022020786 A BR 112022020786A BR 112022020786 A BR112022020786 A BR 112022020786A BR 112022020786 A2 BR112022020786 A2 BR 112022020786A2
- Authority
- BR
- Brazil
- Prior art keywords
- breast cancer
- therapeutic agent
- cancer therapeutic
- agent
- cdk4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020074386 | 2020-04-17 | ||
| PCT/JP2021/015546 WO2021210636A1 (ja) | 2020-04-17 | 2021-04-15 | 乳がん治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020786A2 true BR112022020786A2 (pt) | 2022-11-29 |
Family
ID=78084563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020786A BR112022020786A2 (pt) | 2020-04-17 | 2021-04-15 | Agente terapêutico de câncer de mama |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230149381A1 (https=) |
| EP (1) | EP4122465A4 (https=) |
| JP (1) | JPWO2021210636A1 (https=) |
| KR (1) | KR20230004595A (https=) |
| CN (1) | CN115397415A (https=) |
| AU (1) | AU2021255084B2 (https=) |
| BR (1) | BR112022020786A2 (https=) |
| CA (1) | CA3180128A1 (https=) |
| MX (1) | MX2022012934A (https=) |
| WO (1) | WO2021210636A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| AU2021315234A1 (en) * | 2020-07-31 | 2023-01-19 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR094812A1 (es) * | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| JP2014235614A (ja) | 2013-06-03 | 2014-12-15 | 株式会社ゼネット | 総合学習支援ネットワークシステム及び総合学習支援方法 |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| JP2017217935A (ja) | 2016-06-03 | 2017-12-14 | 株式会社東海理化電機製作所 | ステアリングスイッチ装置 |
| JP2018022750A (ja) | 2016-08-02 | 2018-02-08 | 太陽誘電株式会社 | 積層セラミックコンデンサ |
| WO2018049233A1 (en) * | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
-
2021
- 2021-04-15 EP EP21787967.5A patent/EP4122465A4/en active Pending
- 2021-04-15 KR KR1020227039422A patent/KR20230004595A/ko active Pending
- 2021-04-15 JP JP2022515429A patent/JPWO2021210636A1/ja active Pending
- 2021-04-15 MX MX2022012934A patent/MX2022012934A/es unknown
- 2021-04-15 CA CA3180128A patent/CA3180128A1/en active Pending
- 2021-04-15 CN CN202180028460.3A patent/CN115397415A/zh active Pending
- 2021-04-15 US US17/918,829 patent/US20230149381A1/en not_active Abandoned
- 2021-04-15 BR BR112022020786A patent/BR112022020786A2/pt unknown
- 2021-04-15 WO PCT/JP2021/015546 patent/WO2021210636A1/ja not_active Ceased
- 2021-04-15 AU AU2021255084A patent/AU2021255084B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022012934A (es) | 2022-11-08 |
| EP4122465A1 (en) | 2023-01-25 |
| US20230149381A1 (en) | 2023-05-18 |
| CA3180128A1 (en) | 2021-10-21 |
| AU2021255084B2 (en) | 2026-04-02 |
| KR20230004595A (ko) | 2023-01-06 |
| CN115397415A (zh) | 2022-11-25 |
| AU2021255084A1 (en) | 2022-12-08 |
| JPWO2021210636A1 (https=) | 2021-10-21 |
| WO2021210636A1 (ja) | 2021-10-21 |
| EP4122465A4 (en) | 2024-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020786A2 (pt) | Agente terapêutico de câncer de mama | |
| PY1972032A (es) | Combinaciones para tratamientos de ehna/ehgna y enfermedades relacionadas | |
| MX2023014028A (es) | Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. | |
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| Luo et al. | Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells | |
| PE20251690A1 (es) | Compuestos de indazol sustituidos con piperazina como inhibidores de parg | |
| AR101504A1 (es) | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| AR133968A1 (es) | Nuevo compuesto derivado de ftalazina como inhibidor de sos1 y uso del mismo | |
| MX381588B (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
| MX2018006329A (es) | Agente terapeutico para cancer de mama. | |
| MX2025012087A (es) | Piridazinonas y metodos de uso de estas | |
| PE20110929A1 (es) | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor 2 adrenergico | |
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| BR112023017648A2 (pt) | Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk | |
| MX2020008610A (es) | Agente terapeutico para carcinoma hepatocelular. | |
| CL2020000271A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina. | |
| EP3991742A4 (en) | CORONAVIRUS THERAPEUTIC THAT COMPRISES ELAEOCARPUS SYLVESTRIS EXTRACT AS AN ACTIVE SUBSTANCE | |
| PE20210928A1 (es) | Mezclas pesticidas que comprenden indazoles | |
| AR126392A1 (es) | Terapia combinada para el tratamiento de enfermedades del hígado | |
| BR112021026809A2 (pt) | Terapia de combinação de agonistas de gpr119 e inibidores de dpp-4 | |
| CL2024001777A1 (es) | Derivados de ftalazina como moduladores de piruvato quinasa | |
| BR112023017689A2 (pt) | Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida) |